Vari S, et al. - In this retrospective analysis. researchers assessed whether clinical outcome in patients with metastatic melanomas could be predicted by the first 18F-FDG PET/CT scan performed after the completion of 4 cycles of Ipilimumab treatment. They analyzed 26 patients who performed a PET/CT scan before treatment (PET0), after 4 cycles of Ipilimumab (PET1) and at least an additional later evaluation without starting new therapeutic regimen (PET2). Using PERCIST criteria, response to treatment was assessed. A total of 69 metastatic lesions were also singularly analyzed. According to findings, the definitive response to treatment was not always indicated by the first PET/CT evaluation after IPI. A new therapeutic line can be considered to be initiated for progressive metabolic disease (PMD). An early PET/CT restaging was recommended in all other cases and in particular for stable metabolic disease (SMD) in order to confirm the patient clinical outcome.